

## PHARMANUTRA AT THE AIM ITALIA CONFERENCE DRIVEN BY THE POSITIVE ANALYST FORECASTS

***Yesterday in London, the key event focusing on Italian companies in the AIM segment. BUY rating with increased target price estimates in the equity research published by CFO SIM (TP 27.70 € increased by +35.8% compared to last estimate) and Alantra (TP 25.00 € increased by +22% compared to last estimate)***

Pisa, 22<sup>nd</sup> October – [PharmaNutra S.p.A.](#), leading pharmaceutical company in the iron-based nutritional supplements sector, was among the stars of the “Aim Italia Conference”, organised yesterday by Borsa Italiana, the Italian Stock Exchange, in London to offer Italian and international investors and analysts the opportunity to review the results achieved and the future prospects for dynamic and competitive SMEs quoted on the AIM Italia market.

PharmaNutra, represented by the President, Andrea Lacorte, the Vice President, Roberto Lacorte, and the COO, Carlo Volpi, met with many international investors attracted by the Group's path of growth, illustrating its strategies for growth and expansion on new markets.

The Company's excellent performance has also emerged in recent studies published by the Alantra and CFO SIM analysts. Following the Group's positive results in the first half of 2019, as well as the confirmation of its “BUY” rating, both operators have increased their target price estimates of the Company, from 21.50 to 25.00 EUR (+22%) in the case of Alantra and from 23.30 to 27.70 EUR (+35.8%) in the study published by CFO SIM.

The increase in target price expectations derives from a number of factors. The research highlights the soundness of the overall results and integrate a further increase in national and international sales in their forecasts, deriving from the new export distribution contracts and the acceleration of new proprietary products, including UltraMag® and ApportAL®, on the Italian domestic market following the Group's continuous investments in Research and Development.

**Roberto Lacorte, Vice President of PharmaNutra, commented:** *“We discussed our results and prospects with investors, firmly convinced of the development path we have undertaken which will confirm the Group's position as a key chemical and pharmaceutical industrial concern. This is all thanks to the soundness and constant growth of our accounts which, along with a proportionate growth in staff numbers, the new products being launched and our penetration of new foreign markets, allow us to look enthusiastically towards a long-term future.”*

**PharmaNutra S.p.A.**

*Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 91 of them published and with more than 6000 subjects treated with the supplements. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

<http://www.PharmaNutra.it>

For Information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b

56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

investorrelation@pharmanutra.it

**Nomad & Specialist**

CFO SIM S.p.A.

Via dell'Annunciata

23/4

20121 Milan

Tel. +39 02 303431

ecm@cfosim.com

**Press Office**

Spriano Communication&Partners

Tel. +39 02 83635708

Matteo Russo

Mob. +39 347 9834881

mrusso@sprianocommunication.com

Cristina Tronconi

Mob. +39 346 0477901

ctronconi@sprianocommunication.com